Translational Dysregulation in Cancer: Molecular Insights and Potential Clinical Applications in Biomarker Development
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Although transcript levels have been traditionally used as a surrogate measure of gene expression, it is increasingly recognized that the latter is extensively and dynamically modulated at the level of translation (messenger RNA to protein). Over the recent years, significant progress has been made in dissecting the complex posttranscriptional mechanisms that regulate gene expression. This advancement in knowledge came hand in hand with the progress made in the methodologies to study translation both at gene-specific as well as global genomic level. The majority of translational control is exerted at the level of initiation; nonetheless, protein synthesis can be modulated at the level of translation elongation, termination, and recycling. Sequence and structural elements and epitranscriptomic modifications of individual transcripts allow for dynamic gene-specific modulation of translation. Cancer cells usurp the regulatory mechanisms that govern translation to carry out translational programs that lead to the phenotypic hallmarks of cancer. Translation is a critical nexus in neoplastic transformation. Multiple oncogenes and signaling pathways that are activated, upregulated, or mutated in cancer converge on translation and their transformative impact "bottlenecks" at the level of translation. Moreover, this translational dysregulation allows cancer cells to adapt to a diverse array of stresses associated with a hostile microenviroment and antitumor therapies. All elements involved in the process of translation, from the transcriptional template, the components of the translational machinery, to the proteins that interact with the transcriptome, have been found to be qualitatively and/or quantitatively perturbed in cancer. This review discusses the regulatory mechanisms that govern translation in normal cells and how translation becomes dysregulated in cancer leading to the phenotypic hallmarks of malignancy. We also discuss how dysregulated mediators or components of translation can be utilized as biomarkers with potential diagnostic, prognostic, or predictive significance. Such biomarkers have the potential advantage of uniform applicability in the face of inherent tumor heterogeneity and deoxyribonucleic acid instability. As translation becomes increasingly recognized as a process gone awry in cancer and agents are developed to target it, the utility and significance of these potential biomarkers is expected to increase.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global quantification of mammalian gene expression control
Schwanhäusser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., Chen, W., & Selbach, M. (2011) · Nature · doi:10.1038/nature10098 · Cited by 6,566 · cited 4×
“Curr Opin Genet Dev (2013) 23(1):29–34.”
BackgroundInfluentialComprehensive Analysis of mRNA Methylation Reveals Enrichment in 3′ UTRs and near Stop Codons
Meyer, K. D., Saletore, Y., Zumbo, P., Elemento, O., Mason, C. E., & Jaffrey, S. R. (2012) · Cell · doi:10.1016/j.cell.2012.05.003 · Cited by 4,223
Ingolia, N. T., Lareau, L. F., & Weissman, J. S. (2011) · Cell · doi:10.1016/j.cell.2011.10.002 · Cited by 2,187 · cited 2×
“Ribosome profiling has shown that global translation elongation rates are remarkably consistent across diverse classes of transcripts (96).”
BackgroundTowards a molecular understanding of microRNA-mediated gene silencing
Jonas, S., & Izaurralde, E. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3965 · Cited by 1,872 · cited 1×
“The 3′ UTRs undergo epitranscriptomic modifications and contain miRNA-binding sites; the latter silence gene expression by translational repression and mRNA destabilization (106, 107).”
BackgroundReinitiation involving upstream ORFs regulates ATF4 mRNA translation in mammalian cells
Vattem, K. M., & Wek, R. C. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400541101 · Cited by 1,696 · cited 6×
“This has been exemplified by the modulation of the expression of the transcription factor ATF4 (182).”
BackgroundInfluentialMayr, C., & Bartel, D. P. (2009) · Cell · doi:10.1016/j.cell.2009.06.016 · Cited by 1,613 · cited 2×
“Through a process called alternative cleavage and polyadenylation (109), cells can modulate the length of the 3′ UTR and consequently, by retaining or excluding miRNA- or RNA protein binding sites, regulate the function, stability, localization and translation efficiency of the respective mRNAs.”
BackgroundTargeting the translation machinery in cancer
Bhat, M., Robichaud, N., Hulea, L., Sonenberg, N., Pelletier, J., & Topisirovic, I. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4505 · Cited by 799 · cited 3×
“Other transcription factors can also modulate eIF4F assembly and activity (66).”
BackgroundInfluentialThe Scanning Mechanism of Eukaryotic Translation Initiation
Hinnebusch, A. G. (2014) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060713-035802 · Cited by 798
Transcriptome-wide Analysis of Regulatory Interactions of the RNA-Binding Protein HuR
Lebedeva, S., Jens, M., Theil, K., Schwanhäusser, B., Selbach, M., Landthaler, M., & Rajewsky, N. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.06.008 · Cited by 716 · cited 2×
“Since translation is a downstream process into which diverse arrays of oncogenic pathways converge, one potential advantage Abbreviations: 4E-BP, eIF4E-binding protein; A, adenosine; A-site, acceptor site; ABCE1, ATP-binding cassette subfamily E member 1; ADAR, adenosine deaminase, RNA-specific; ADARB1/2, adenosine de…”
RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer
Wolfe, A. L., Singh, K., Zhong, Y., Drewe, P., Rajasekhar, V. K., Sanghvi, V. R., Mavrakis, K. J., Jiang, M., Roderick, J. E., Van der Meulen, J., et al. (2014) · Nature · doi:10.1038/nature13485 · Cited by 635 · cited 3×
“Transcripts of many oncogenes, superenhancer-associated transcription factors, and epigenetic regulators are eIF4A-dependent and, accordingly, silvestrol-sensitive (104).”
BackgroundInfluentialYang, H.-S., Jansen, A. P., Komar, A. A., Zheng, X., Merrick, W. C., Costes, S., Lockett, S. J., Sonenberg, N., & Colburn, N. H. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.1.26-37.2003 · Cited by 494 · cited 1×
“The phosphorylation of PDCD4 by S6Ks leads to its proteasomal degradation and the liberation of eIF4A from PDCD4-eIF4A inhibitory complexes (169).”
BackgroundEpitranscriptome sequencing technologies: decoding RNA modifications
Li, X., Xiong, X., & Yi, C. (2017) · Nature Methods · doi:10.1038/nmeth.4110 · Cited by 447
Rajasekhar, V. K., Viale, A., Socci, N. D., Wiedmann, M., Hu, X., & Holland, E. C. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00395-2 · Cited by 420
New frontiers in translational control of the cancer genome
Truitt, M. L., & Ruggero, D. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.27 · Cited by 378 · cited 1×
“Fostering Oncogenic Translation The human genome contains 61 sense codons, many of which are synonymous on the basis that they encode the same amino acid (194).”
Targeting the eIF4F Translation Initiation Complex: A Critical Nexus for Cancer Development
Pelletier, J., Graff, J., Ruggero, D., & Sonenberg, N. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2789 · Cited by 367 · cited 4×
“eIF4A in mammals exists two highly related isoforms [eIF4AI and eIF4AII; a third isoform, eIF4AIII, acts as a translation initiation factor specifically for the nuclear cap-binding complex bound mRNAs and efficiently unwinds secondary structures in their respective 5′ UTRs (59)] which, despite being interchangeable in…”
BackgroundInfluentialUpstream ORFs are prevalent translational repressors in vertebrates
Johnstone, T. G., Bazzini, A. A., & Giraldez, A. J. (2016) · The EMBO Journal · doi:10.15252/embj.201592759 · Cited by 346 · cited 1×
“This is particularly relevant in the human transcriptome where nearly half of all transcripts are at least computationally predicted to contain upstream or overlapping reading frames whose translation in general represses the translation of the downstream coding sequence (102).”
BackgroundAn oxygen-regulated switch in the protein synthesis machinery
Uniacke, J., Holterman, C. E., Lachance, G., Franovic, A., Jacob, M. D., Fabian, M. R., Payette, J., Holcik, M., Pause, A., & Lee, S. (2012) · Nature · doi:10.1038/nature11055 · Cited by 319 · cited 3×
“Besides eIF4E and eIF4F, other cap-binding proteins and complexes have been described (68, 69) that drive selective translation.”
BackgroundMTOR inhibitors in cancer therapy
Xie, J., Wang, X., & Proud, C. G. (2016) · F1000Research · doi:10.12688/f1000research.9207.1 · Cited by 266 · cited 1×
“Each complex has distinct substrates and, accordingly, regulates different cellular processes (161).”
BackgroundLoss of PDCD4 expression in human lung cancer correlates with tumour progression and prognosis
Chen, Y., Knösel, T., Kristiansen, G., Pietas, A., Garber, M. E., Matsuhashi, S., Ozaki, I., & Petersen, I. (2003) · The Journal of Pathology · doi:10.1002/path.1378 · Cited by 265
Hansen, T. V. O., Hammer, N. A., Nielsen, J., Madsen, M., Dalbaeck, C., Wewer, U. M., Christiansen, J., & Nielsen, F. C. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.10.4448-4464.2004 · Cited by 251 · cited 1×
“The IGF2BPs are oncofetal proteins that are normally expressed only during embryogenesis (121); however, the expression of IGF2BP1 and IGF2BP3 is induced in various malignancies.”
BackgroundMudduluru, G., Medved, F., Grobholz, R., Jost, C., Gruber, A., Leupold, J. H., Post, S., Jansen, A., Colburn, N. H., & Allgayer, H. (2007) · Cancer · doi:10.1002/cncr.22983 · Cited by 196
c-Myc and eIF4F Are Components of a Feedforward Loop that Links Transcription and Translation
Lin, C.-J., Cencic, R., Mills, J. R., Robert, F., & Pelletier, J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5876 · Cited by 180
Hoffman, Y., Bublik, D. R., P. Ugalde, A., Elkon, R., Biniashvili, T., Agami, R., Oren, M., & Pilpel, Y. (2016) · PLOS Genetics · doi:10.1371/journal.pgen.1005879 · Cited by 90
Research works printed but not linked: 184
- Sonenberg, 2009, Regulation of translation initiation in eukaryotes: mechanisms and biological targets, Cell, 136, 731, 10.1016/j.cell.2009.01.042 · DOI · Paper page
- Boussemart, 2014, eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies, Nature, 513, 105, 10.1038/nature13572 · DOI · Paper page
- Cammas, 2016, hnRNP A1-mediated translational regulation of the G quadruplex-containing RON receptor tyrosine kinase mRNA linked to tumor progression, Oncotarget, 7, 16793, 10.18632/oncotarget.7589 · DOI
- Habibi, 2008, Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes, Breast Cancer Res, 10, R86, 10.1186/bcr2156 · doi:10.1186/bcr2156
- Heinonen, 2005, Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma, Cancer Res, 65, 2157, 10.1158/0008-5472.CAN-04-3765 · DOI · Paper page
- Heinonen, 2007, Prognostic role of HuR in hereditary breast cancer, Clin Cancer Res, 13, 6959, 10.1158/1078-0432.CCR-07-1432 · DOI · Paper page
- Walter, 2009, IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype, Hum Pathol, 40, 1528, 10.1016/j.humpath.2009.05.005 · DOI
- Zhou, 2006, Eukaryotic initiation factor 4E (eIF4E) and angiogenesis: prognostic markers for breast cancer, BMC Cancer, 6, 231, 10.1186/1471-2407-6-231 · DOI
- Flowers, 2009, Eukaryotic initiation factor 4E overexpression in triple-negative breast cancer predicts a worse outcome, Surgery, 146, 220, 10.1016/j.surg.2009.05.010 · doi:10.1016/j.surg.2009.05.010
- Modelska, 2015, The malignant phenotype in breast cancer is driven by eIF4A1-mediated changes in the translational landscape, Cell Death Dis, 6, e1603, 10.1038/cddis.2014.542 · DOI · Paper page
- McClusky, 2005, A prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-positive breast cancer, Ann Surg, 242, 584, 10.1097/01.sla.0000184224.55949.90 · DOI
- Yin, 2014, Overexpression of eukaryotic initiation factor 4E is correlated with increased risk for systemic dissemination in node-positive breast cancer patients, J Am Coll Surg, 218, 663, 10.1016/j.jamcollsurg.2013.12.020 · doi:10.1016/j.jamcollsurg.2013.12.020
- Li, 2002, Prospective study of eukaryotic initiation factor 4E protein elevation and breast cancer outcome, Ann Surg, 235, 732, 10.1097/00000658-200205000-00016 · DOI
- Rojo, 2007, 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis, Clin Cancer Res, 13, 81, 10.1158/1078-0432.CCR-06-1560 · DOI · Paper page
- Silvera, 2009, Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer, Nat Cell Biol, 11, 903, 10.1038/ncb1900 · DOI · Paper page
- Marcel, 2013, p53 acts as a safeguard of translational control by regulating fibrillarin and rRNA methylation in cancer, Cancer Cell, 24, 318, 10.1016/j.ccr.2013.08.013 · DOI · Paper page
- Delaunay, 2016, Elp3 links tRNA modification to IRES-dependent translation of LEF1 to sustain metastasis in breast cancer, J Exp Med, 213, 2503, 10.1084/jem.20160397 · DOI · Paper page
- Zhao, 2016, High expression of Y-box-binding protein 1 correlates with poor prognosis and early recurrence in patients with small invasive lung adenocarcinoma, Onco Targets Ther, 9, 2683, 10.2147/OTT.S99939 · DOI
- Wang, 2011, Cytoplasmic HuR expression correlates with angiogenesis, lymphangiogenesis, and poor outcome in lung cancer, Med Oncol, 28, S577, 10.1007/s12032-010-9734-6 · DOI
- Kim, 2011, Expression of HuR, COX-2, and survivin in lung cancers; cytoplasmic HuR stabilizes cyclooxygenase-2 in squamous cell carcinomas, Mod Pathol, 24, 1336, 10.1038/modpathol.2011.90 · DOI
- Spinola, 2005, Identification and functional characterization of the candidate tumor suppressor gene TRIT1 in human lung cancer, Oncogene, 24, 5502, 10.1038/sj.onc.1208687 · DOI
- Zhou, 2013, Overexpression of HnRNP A1 promotes tumor invasion through regulating CD44v6 and indicates poor prognosis for hepatocellular carcinoma, Int J Cancer, 132, 1080, 10.1002/ijc.27742 · DOI
- Shiraiwa, 2016, Nuclear Y-box-binding protein-1 expression predicts poor clinical outcome in stage III colorectal cancer, Anticancer Res, 36, 3781
- Shinkai, 2016, Nuclear expression of Y-box binding protein-1 is associated with poor prognosis in patients with pancreatic cancer and its knockdown inhibits tumor growth and metastasis in mice tumor models, Int J Cancer, 139, 433, 10.1002/ijc.30075 · DOI
- Zhang, 2015, The expression level and prognostic value of Y-box binding protein-1 in rectal cancer, PLoS One, 10, e0119385, 10.1371/journal.pone.0119385 · DOI
- Tatarian, 2016, Cytoplasmic HuR status predicts disease-free survival in resected pancreatic cancer: a post-hoc analysis from the international phase III ESPAC-3 clinical trial, Ann Surg, 10.1097/SLA.0000000000002088 · doi:10.1097/sla.0000000000002088
- Mrena, 2005, Cyclooxygenase-2 is an independent prognostic factor in gastric cancer and its expression is regulated by the messenger RNA stability factor HuR, Clin Cancer Res, 11, 7362, 10.1158/1078-0432.CCR-05-0764 · DOI · Paper page
- Denkert, 2006, Expression of the ELAV-like protein HuR in human colon cancer: association with tumor stage and cyclooxygenase-2, Mod Pathol, 19, 1261, 10.1038/modpathol.3800645 · DOI · Paper page
- Okada, 2012, Oncofetal protein, IMP-3, a potential marker for prediction of postoperative peritoneal dissemination in gastric adenocarcinoma, J Surg Oncol, 105, 780, 10.1002/jso.22108 · DOI
- Chen, 2013, Expression of insulin-like growth factor II mRNA-binding protein 3 predicts early recurrence and poor prognosis in intrahepatic cholangiocarcinoma, Int J Surg, 11, 85, 10.1016/j.ijsu.2012.11.021 · DOI
- Li, 2009, IMP3 is a novel prognostic marker that correlates with colon cancer progression and pathogenesis, Ann Surg Oncol, 16, 3499, 10.1245/s10434-009-0648-5 · DOI
- Lin, 2013, Insulin-like growth factor-II mRNA-binding protein 3 predicts a poor prognosis for colorectal adenocarcinoma, Oncol Lett, 6, 740, 10.3892/ol.2013.1458 · DOI
- Diab-Assaf, 2015, Expression of eukaryotic initiation factor 4E and 4E binding protein 1 in colorectal carcinogenesis, Int J Clin Exp Pathol, 8, 404
- Chen, 2004, Expression of eukaryotic initiation factor 4E in gastric adenocarcinoma and its association with clinical outcome, J Surg Oncol, 86, 22, 10.1002/jso.20037 · DOI
- Chao, 2015, eIF4E binding protein 1 expression is associated with clinical survival outcomes in colorectal cancer, Oncotarget, 6, 24092, 10.18632/oncotarget.4483 · DOI
- Fassan, 2010, Programmed cell death 4 protein in esophageal cancer, Oncol Rep, 24, 135, 10.3892/or_00000838 · DOI · Paper page
- Fassan, 2010, Programmed cell death 4 (PDCD4) expression during multistep Barrett’s carcinogenesis, J Clin Pathol, 63, 692, 10.1136/jcp.2010.078253 · DOI
- Huang, 2016, HNRNPC as a candidate biomarker for chemoresistance in gastric cancer, Tumour Biol, 37, 3527, 10.1007/s13277-015-4144-1 · DOI
- Shiota, 2016, Potential role for YB-1 in castration-resistant prostate cancer and resistance to enzalutamide through the androgen receptor V7, J Natl Cancer Inst, 108, djw005, 10.1093/jnci/djw005 · DOI
- Furic, 2010, eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression, Proc Natl Acad Sci U S A, 107, 14134, 10.1073/pnas.1005320107 · DOI · Paper page
- Nishio, 2014, Nuclear Y-box-binding protein-1 is a poor prognostic marker and related to epidermal growth factor receptor in uterine cervical cancer, Gynecol Oncol, 132, 703, 10.1016/j.ygyno.2014.01.045 · doi:10.1016/j.ygyno.2014.01.045
- Denkert, 2004, Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression, Cancer Res, 64, 189, 10.1158/0008-5472.CAN-03-1987 · DOI · Paper page
- Lim, 2007, Expression of HuR is associated with increased cyclooxygenase-2 expression in uterine cervical carcinoma, Int J Gynecol Pathol, 26, 229, 10.1097/01.pgp.0000236946.82334.07 · DOI
- Kobel, 2007, Expression of the RNA-binding protein IMP1 correlates with poor prognosis in ovarian carcinoma, Oncogene, 26, 7584, 10.1038/sj.onc.1210563 · DOI
- Kobel, 2009, IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype, Mod Pathol, 22, 469, 10.1038/modpathol.2008.206 · DOI
- Fadare, 2013, Expression of the oncofetal protein IGF2BP3 in endometrial clear cell carcinoma: assessment of frequency and significance, Hum Pathol, 44, 1508, 10.1016/j.humpath.2012.12.003 · DOI
- Castellvi, 2009, Cell signaling in endometrial carcinoma: phosphorylated 4E-binding protein-1 expression in endometrial cancer correlates with aggressive tumors and prognosis, Hum Pathol, 40, 1418, 10.1016/j.humpath.2008.12.019 · DOI
- Wang, 2008, Expression and prognostic significance of PDCD4 in human epithelial ovarian carcinoma, Anticancer Res, 28, 2991
- Zheng, 2016, YB-1, a new biomarker of glioma progression, is associated with the prognosis of glioma patients, Acta Biochim Biophys Sin (Shanghai), 48, 318, 10.1093/abbs/gmw012 · DOI
- Bell, 2015, IGF2BP1 harbors prognostic significance by gene gain and diverse expression in neuroblastoma, J Clin Oncol, 33, 1285, 10.1200/JCO.2014.55.9880 · DOI
- Gao, 2009, PDCD4 gene silencing in gliomas is associated with 5’CpG island methylation and unfavourable prognosis, J Cell Mol Med, 13, 4257, 10.1111/j.1582-4934.2008.00497.x · DOI · Paper page
- Leprivier, 2013, The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation, Cell, 153, 1064, 10.1016/j.cell.2013.04.055 · DOI · Paper page
- Macari, 2016, TRM6/61 connects PKCalpha with translational control through tRNAi(Met) stabilization: impact on tumorigenesis, Oncogene, 35, 1785, 10.1038/onc.2015.244 · DOI
- Jackson, 2010, The mechanism of eukaryotic translation initiation and principles of its regulation, Nat Rev Mol Cell Biol, 11, 113, 10.1038/nrm2838 · DOI · Paper page
- Choe, 2014, eIF4AIII enhances translation of nuclear cap-binding complex-bound mRNAs by promoting disruption of secondary structures in 5’UTR, Proc Natl Acad Sci U S A, 111, E4577, 10.1073/pnas.1409695111 · DOI
- Galicia-Vazquez, 2012, A cellular response linking eIF4AI activity to eIF4AII transcription, RNA, 18, 1373, 10.1261/rna.033209.112 · DOI · Paper page
- Parsyan, 2011, mRNA helicases: the tacticians of translational control, Nat Rev Mol Cell Biol, 12, 235, 10.1038/nrm3083 · DOI · Paper page
- Rogers, 1999, Biochemical and kinetic characterization of the RNA helicase activity of eukaryotic initiation factor 4A, J Biol Chem, 274, 12236, 10.1074/jbc.274.18.12236 · DOI · Paper page
- Rozovsky, 2008, Interactions between eIF4AI and its accessory factors eIF4B and eIF4H, RNA, 14, 2136, 10.1261/rna.1049608 · DOI · Paper page
- Feoktistova, 2013, Human eIF4E promotes mRNA restructuring by stimulating eIF4A helicase activity, Proc Natl Acad Sci U S A, 110, 13339, 10.1073/pnas.1303781110 · DOI · Paper page
- von der Haar, 2004, The mRNA cap-binding protein eIF4E in post-transcriptional gene expression, Nat Struct Mol Biol, 11, 503, 10.1038/nsmb779 · DOI · Paper page
- Lee, 2016, eIF3d is an mRNA cap-binding protein that is required for specialized translation initiation, Nature, 536, 96, 10.1038/nature18954 · DOI · Paper page
- Uniacke, 2014, Cancer cells exploit eIF4E2-directed synthesis of hypoxia response proteins to drive tumor progression, Cancer Res, 74, 1379, 10.1158/0008-5472.CAN-13-2278 · DOI · Paper page
- Timpano, 2016, Human cells cultured under physiological oxygen utilize two cap-binding proteins to recruit distinct mRNAs for translation, J Biol Chem, 291, 10772, 10.1074/jbc.M116.717363 · DOI
- Lee, 2015, eIF3 targets cell-proliferation messenger RNAs for translational activation or repression, Nature, 522, 111, 10.1038/nature14267 · DOI · Paper page
- King, 2010, The role of IRES trans-acting factors in regulating translation initiation, Biochem Soc Trans, 38, 1581, 10.1042/BST0381581 · DOI · Paper page
- Walters, 2016, Cap-independent translational control of carcinogenesis, Front Oncol, 6, 128, 10.3389/fonc.2016.00128 · DOI
- Komar, 2011, Cellular IRES-mediated translation: the war of ITAFs in pathophysiological states, Cell Cycle, 10, 229, 10.4161/cc.10.2.14472 · DOI · Paper page
- Chappell, 2004, Biochemical and functional analysis of a 9-nt RNA sequence that affects translation efficiency in eukaryotic cells, Proc Natl Acad Sci U S A, 101, 9590, 10.1073/pnas.0308759101 · DOI
- Meng, 2010, The human IGF1R IRES likely operates through a Shine-Dalgarno-like interaction with the G961 loop (E-site) of the 18S rRNA and is kinetically modulated by a naturally polymorphic polyU loop, J Cell Biochem, 110, 531, 10.1002/jcb.22569 · DOI
- Xue, 2015, RNA regulons in Hox 5’UTRs confer ribosome specificity to gene regulation, Nature, 517, 33, 10.1038/nature14010 · DOI · Paper page
- Jack, 2011, rRNA pseudouridylation defects affect ribosomal ligand binding and translational fidelity from yeast to human cells, Mol Cell, 44, 660, 10.1016/j.molcel.2011.09.017 · DOI · Paper page
- Ruggero, 2003, Dyskeratosis congenita and cancer in mice deficient in ribosomal RNA modification, Science, 299, 259, 10.1126/science.1079447 · DOI · Paper page
- Hertz, 2013, Ribosomal protein S25 dependency reveals a common mechanism for diverse internal ribosome entry sites and ribosome shunting, Mol Cell Biol, 33, 1016, 10.1128/MCB.00879-12 · DOI · Paper page
- Spriggs, 2010, Translational regulation of gene expression during conditions of cell stress, Mol Cell, 40, 228, 10.1016/j.molcel.2010.09.028 · DOI · Paper page
- Huez, 1998, Two independent internal ribosome entry sites are involved in translation initiation of vascular endothelial growth factor mRNA, Mol Cell Biol, 18, 6178, 10.1128/MCB.18.11.6178 · DOI · Paper page
- Sherrill, 2004, BCL-2 translation is mediated via internal ribosome entry during cell stress, J Biol Chem, 279, 29066, 10.1074/jbc.M402727200 · DOI · Paper page
- Martineau, 2004, Internal ribosome entry site structural motifs conserved among mammalian fibroblast growth factor 1 alternatively spliced mRNAs, Mol Cell Biol, 24, 7622, 10.1128/MCB.24.17.7622-7635.2004 · DOI
- Blau, 2012, Aberrant expression of c-Jun in glioblastoma by internal ribosome entry site (IRES)-mediated translational activation, Proc Natl Acad Sci U S A, 109, E2875, 10.1073/pnas.1203659109 · DOI
- Dobson, 2013, Dysregulating IRES-dependent translation contributes to over-expression of the aurora A kinase onco-protein, Mol Cancer Res, 11, 887, 10.1158/1541-7786.MCR-12-0707 · DOI
- Nanbru, 1997, Alternative translation of the proto-oncogene c-myc by an internal ribosome entry site, J Biol Chem, 272, 32061, 10.1074/jbc.272.51.32061 · DOI · Paper page
- Stoneley, 1998, C-Myc 5’ untranslated region contains an internal ribosome entry segment, Oncogene, 16, 423, 10.1038/sj.onc.1201763 · DOI · Paper page
- Meng, 2005, The ELAV RNA-stability factor HuR binds the 5’-untranslated region of the human IGF-IR transcript and differentially represses cap-dependent and IRES-mediated translation, Nucleic Acids Res, 33, 2962, 10.1093/nar/gki603 · DOI · Paper page
- Coldwell, 2000, Initiation of Apaf-1 translation by internal ribosome entry, Oncogene, 19, 899, 10.1038/sj.onc.1203407 · DOI · Paper page
- Liu, 2014, Translational reprogramming in cellular stress response, Wiley Interdiscip Rev RNA, 5, 301, 10.1002/wrna.1212 · DOI · Paper page
- Li, 2013, The unexpected roles of eukaryotic translation elongation factors in RNA virus replication and pathogenesis, Microbiol Mol Biol Rev, 77, 253, 10.1128/MMBR.00059-12 · DOI
- Proud, 2015, Regulation and roles of elongation factor 2 kinase, Biochem Soc Trans, 43, 328, 10.1042/BST20140323 · DOI · Paper page
- Alkalaeva, 2006, In vitro reconstitution of eukaryotic translation reveals cooperativity between release factors eRF1 and eRF3, Cell, 125, 1125, 10.1016/j.cell.2006.04.035 · DOI · Paper page
- Jackson, 2012, Termination and post-termination events in eukaryotic translation, Adv Protein Chem Struct Biol, 86, 45, 10.1016/B978-0-12-386497-0.00002-5 · DOI · Paper page
- Pisarev, 2010, The role of ABCE1 in eukaryotic posttermination ribosomal recycling, Mol Cell, 37, 196, 10.1016/j.molcel.2009.12.034 · DOI · Paper page
- Young, 2015, Rli1/ABCE1 recycles terminating ribosomes and controls translation reinitiation in 3’UTRs in vivo, Cell, 162, 872, 10.1016/j.cell.2015.07.041 · DOI · Paper page
- Miettinen, 2015, Modified ribosome profiling reveals high abundance of ribosome protected mRNA fragments derived from 3’ untranslated regions, Nucleic Acids Res, 43, 1019, 10.1093/nar/gku1310 · DOI · Paper page
- Schleich, 2014, DENR-MCT-1 promotes translation re-initiation downstream of uORFs to control tissue growth, Nature, 512, 208, 10.1038/nature13401 · DOI · Paper page
- Jia, 2013, Regulation and dysregulation of 3’UTR-mediated translational control, Curr Opin Genet Dev, 23, 29, 10.1016/j.gde.2012.12.004 · DOI · Paper page
- Iwakawa, 2015, The functions of microRNAs: mRNA decay and translational repression, Trends Cell Biol, 25, 651, 10.1016/j.tcb.2015.07.011 · DOI · Paper page
- Baltz, 2012, The mRNA-bound proteome and its global occupancy profile on protein-coding transcripts, Mol Cell, 46, 674, 10.1016/j.molcel.2012.05.021 · DOI · Paper page
- Glisovic, 2008, RNA-binding proteins and post-transcriptional gene regulation, FEBS Lett, 582, 1977, 10.1016/j.febslet.2008.03.004 · DOI · Paper page
- Brummer, 2013, Modeling the binding specificity of the RNA-binding protein GLD-1 suggests a function of coding region-located sites in translational repression, RNA, 19, 1317, 10.1261/rna.037531.112 · DOI
- Wurth, 2015, RNA-binding proteins, multifaceted translational regulators in cancer, Biochim Biophys Acta, 1849, 881, 10.1016/j.bbagrm.2014.10.001 · DOI
- Grammatikakis, 2017, Posttranslational control of HuR function, Wiley Interdiscip Rev RNA, 8, 10.1002/wrna.1372 · DOI · Paper page
- Mukherjee, 2011, Integrative regulatory mapping indicates that the RNA-binding protein HuR couples pre-mRNA processing and mRNA stability, Mol Cell, 43, 327, 10.1016/j.molcel.2011.06.007 · DOI · Paper page
- Srikantan, 2011, UneCLIPsing HuR nuclear function, Mol Cell, 43, 319, 10.1016/j.molcel.2011.07.016 · DOI
- Wang, 2013, Multiple functions of the RNA-binding protein HuR in cancer progression, treatment responses and prognosis, Int J Mol Sci, 14, 10015, 10.3390/ijms140510015 · DOI · Paper page
- Wang, 2000, HuR regulates cyclin A and cyclin B1 mRNA stability during cell proliferation, EMBO J, 19, 2340, 10.1093/emboj/19.10.2340 · DOI · Paper page
- Kim, 2008, Phosphorylated HuR shuttles in cycles, Cell Cycle, 7, 3124, 10.4161/cc.7.20.6884 · DOI · Paper page
- Riener, 2009, IMP3 expression in lesions of the biliary tract: a marker for high-grade dysplasia and an independent prognostic factor in bile duct carcinomas, Hum Pathol, 40, 1377, 10.1016/j.humpath.2009.01.024 · DOI
- Jiang, 2006, Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study, Lancet Oncol, 7, 556, 10.1016/S1470-2045(06)70732-X · DOI · Paper page
- Jiang, 2008, Combination of quantitative IMP3 and tumor stage: a new system to predict metastasis for patients with localized renal cell carcinomas, Clin Cancer Res, 14, 5579, 10.1158/1078-0432.CCR-08-0504 · DOI
- Sitnikova, 2008, IMP3 predicts aggressive superficial urothelial carcinoma of the bladder, Clin Cancer Res, 14, 1701, 10.1158/1078-0432.CCR-07-2039 · DOI
- Bell, 2013, Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression?, Cell Mol Life Sci, 70, 2657, 10.1007/s00018-012-1186-z · DOI · Paper page
- Bernstein, 1992, Control of c-myc mRNA half-life in vitro by a protein capable of binding to a coding region stability determinant, Genes Dev, 6, 642, 10.1101/gad.6.4.642 · DOI · Paper page
- Faye, 2015, IGF2BP1 controls cell death and drug resistance in rhabdomyosarcomas by regulating translation of cIAP1, Oncogene, 34, 1532, 10.1038/onc.2014.90 · DOI
- Lederer, 2014, The role of the oncofetal IGF2 mRNA-binding protein 3 (IGF2BP3) in cancer, Semin Cancer Biol, 29, 3, 10.1016/j.semcancer.2014.07.006 · DOI · Paper page
- Galardi, 2016, CPEB1 restrains proliferation of glioblastoma cells through the regulation of p27(Kip1) mRNA translation, Sci Rep, 6, 25219, 10.1038/srep25219 · DOI
- Richter, 2007, CPEB: a life in translation, Trends Biochem Sci, 32, 279, 10.1016/j.tibs.2007.04.004 · DOI · Paper page
- Grudzien-Nogalska, 2014, CPEB1 promotes differentiation and suppresses EMT in mammary epithelial cells, J Cell Sci, 127, 2326, 10.1242/jcs.144956 · DOI
- Nagaoka, 2016, CPEB1 mediates epithelial-to-mesenchyme transition and breast cancer metastasis, Oncogene, 35, 2893, 10.1038/onc.2015.350 · DOI
- Ortiz-Zapater, 2011, Key contribution of CPEB4-mediated translational control to cancer progression, Nat Med, 18, 83, 10.1038/nm.2540 · DOI
- Perez-Guijarro, 2016, Lineage-specific roles of the cytoplasmic polyadenylation factor CPEB4 in the regulation of melanoma drivers, Nat Commun, 7, 13418, 10.1038/ncomms13418 · DOI
- Meyer, 2014, The dynamic epitranscriptome: N6-methyladenosine and gene expression control, Nat Rev Mol Cell Biol, 15, 313, 10.1038/nrm3785 · DOI · Paper page
- Gilbert, 2016, Messenger RNA modifications: form, distribution, and function, Science, 352, 1408, 10.1126/science.aad8711 · DOI · Paper page
- Iles, 2013, A variant in FTO shows association with melanoma risk not due to BMI, Nat Genet, 45, 428, 10.1038/ng.2571 · DOI · Paper page
- Garcia-Closas, 2013, Genome-wide association studies identify four ER negative-specific breast cancer risk loci, Nat Genet, 45, 392, 10.1038/ng.2561 · DOI · Paper page
- Molinie, 2016, m(6)A-LAIC-seq reveals the census and complexity of the m(6)A epitranscriptome, Nat Methods, 13, 692, 10.1038/nmeth.3898 · DOI · Paper page
- Meyer, 2015, 5’ UTR m(6)A promotes cap-independent translation, Cell, 163, 999, 10.1016/j.cell.2015.10.012 · DOI · Paper page
- Zhou, 2015, Dynamic m(6)A mRNA methylation directs translational control of heat shock response, Nature, 526, 591, 10.1038/nature15377 · DOI · Paper page
- Jiang, 2017, RNA editing-dependent epitranscriptome diversity in cancer stem cells, Nat Rev Cancer, 17, 381, 10.1038/nrc.2017.23 · DOI
- Bahn, 2015, Genomic analysis of ADAR1 binding and its involvement in multiple RNA processing pathways, Nat Commun, 6, 6355, 10.1038/ncomms7355 · DOI · Paper page
- Barna, 2008, Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency, Nature, 456, 971, 10.1038/nature07449 · DOI · Paper page
- Truitt, 2015, Differential requirements for eIF4E dose in normal development and cancer, Cell, 162, 59, 10.1016/j.cell.2015.05.049 · DOI · Paper page
- Shahbazian, 2010, eIF4B controls survival and proliferation and is regulated by proto-oncogenic signaling pathways, Cell Cycle, 9, 4106, 10.4161/cc.9.20.13630 · DOI
- Lazaris-Karatzas, 1990, Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5’ cap, Nature, 345, 544, 10.1038/345544a0 · DOI · Paper page
- Mamane, 2004, eIF4E – from translation to transformation, Oncogene, 23, 3172, 10.1038/sj.onc.1207549 · DOI · Paper page
- Yanagiya, 2012, Translational homeostasis via the mRNA cap-binding protein, eIF4E, Mol Cell, 46, 847, 10.1016/j.molcel.2012.04.004 · DOI · Paper page
- Koromilas, 1992, mRNAs containing extensive secondary structure in their 5’ non-coding region translate efficiently in cells overexpressing initiation factor eIF-4E, EMBO J, 11, 4153, 10.1002/j.1460-2075.1992.tb05508.x · DOI · Paper page
- Niedzwiecka, 2002, Biophysical studies of eIF4E cap-binding protein: recognition of mRNA 5’ cap structure and synthetic fragments of eIF4G and 4E-BP1 proteins, J Mol Biol, 319, 615, 10.1016/S0022-2836(02)00328-5 · DOI · Paper page
- Topisirovic, 2003, The proline-rich homeodomain protein, PRH, is a tissue-specific inhibitor of eIF4E-dependent cyclin D1 mRNA transport and growth, EMBO J, 22, 689, 10.1093/emboj/cdg069 · DOI · Paper page
- Ueda, 2004, Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development, Mol Cell Biol, 24, 6539, 10.1128/MCB.24.15.6539-6549.2004 · DOI · Paper page
- Scheper, 2002, Phosphorylation of eukaryotic initiation factor 4E markedly reduces its affinity for capped mRNA, J Biol Chem, 277, 3303, 10.1074/jbc.M103607200 · DOI · Paper page
- Zuberek, 2003, Phosphorylation of eIF4E attenuates its interaction with mRNA 5’ cap analogs by electrostatic repulsion: intein-mediated protein ligation strategy to obtain phosphorylated protein, RNA, 9, 52, 10.1261/rna.2133403 · DOI · Paper page
- Pettersson, 2015, Genetic and pharmacologic inhibition of eIF4E reduces breast cancer cell migration, invasion, and metastasis, Cancer Res, 75, 1102, 10.1158/0008-5472.CAN-14-1996 · DOI
- Robichaud, 2015, Phosphorylation of eIF4E promotes EMT and metastasis via translational control of SNAIL and MMP-3, Oncogene, 34, 2032, 10.1038/onc.2014.146 · DOI · Paper page
- Gandin, 2016, mTORC1 and CK2 coordinate ternary and eIF4F complex assembly, Nat Commun, 7, 11127, 10.1038/ncomms11127 · DOI · Paper page
- Roux, 2012, Regulation of mRNA translation by signaling pathways, Cold Spring Harb Perspect Biol, 4, a012252, 10.1101/cshperspect.a012252 · DOI · Paper page
- Alain, 2012, eIF4E/4E-BP ratio predicts the efficacy of mTOR targeted therapies, Cancer Res, 72, 6468, 10.1158/0008-5472.CAN-12-2395 · DOI · Paper page
- Tsukumo, 2016, Translation control during prolonged mTORC1 inhibition mediated by 4E-BP3, Nat Commun, 7, 11776, 10.1038/ncomms11776 · DOI
- Raught, 2004, Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases, EMBO J, 23, 1761, 10.1038/sj.emboj.7600193 · DOI · Paper page
- Shahbazian, 2006, The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity, EMBO J, 25, 2781, 10.1038/sj.emboj.7601166 · DOI · Paper page
- Shahbazian, 2010, Control of cell survival and proliferation by mammalian eukaryotic initiation factor 4B, Mol Cell Biol, 30, 1478, 10.1128/MCB.01218-09 · DOI · Paper page
- Mayer, 2004, mTOR-dependent activation of the transcription factor TIF-IA links rRNA synthesis to nutrient availability, Genes Dev, 18, 423, 10.1101/gad.285504 · DOI · Paper page
- Michels, 2010, mTORC1 directly phosphorylates and regulates human MAF1, Mol Cell Biol, 30, 3749, 10.1128/MCB.00319-10 · DOI · Paper page
- Wei, 2009, Mechanisms of regulation of RNA polymerase III-dependent transcription by TORC1, EMBO J, 28, 2220, 10.1038/emboj.2009.179 · DOI · Paper page
- Fernandez, 2003, Genomic targets of the human c-Myc protein, Genes Dev, 17, 1115, 10.1101/gad.1067003 · DOI · Paper page
- Lin, 2009, c-Myc and eIF4F constitute a feedforward loop that regulates cell growth: implications for anticancer therapy, Cancer Res, 69, 7491, 10.1158/0008-5472.CAN-09-0813 · DOI
- Khanna-Gupta, 2012, Up-regulation of translation eukaryotic initiation factor 4E in nucleophosmin 1 haploinsufficient cells results in changes in CCAAT enhancer-binding protein alpha activity: implications in myelodysplastic syndrome and acute myeloid leukemia, J Biol Chem, 287, 32728, 10.1074/jbc.M112.373274 · DOI
- Hariri, 2013, The eukaryotic translation initiation factor eIF4E is a direct transcriptional target of NF-kappaB and is aberrantly regulated in acute myeloid leukemia, Leukemia, 27, 2047, 10.1038/leu.2013.73 · DOI
- Yi, 2013, Hypoxia-inducible factor-1alpha (HIF-1alpha) promotes cap-dependent translation of selective mRNAs through up-regulating initiation factor eIF4E1 in breast cancer cells under hypoxia conditions, J Biol Chem, 288, 18732, 10.1074/jbc.M113.471466 · DOI · Paper page
- Topisirovic, 2009, Stability of eukaryotic translation initiation factor 4E mRNA is regulated by HuR, and this activity is dysregulated in cancer, Mol Cell Biol, 29, 1152, 10.1128/MCB.01532-08 · DOI · Paper page
- Koromilas, 2015, Roles of the translation initiation factor eIF2alpha serine 51 phosphorylation in cancer formation and treatment, Biochim Biophys Acta, 1849, 871, 10.1016/j.bbagrm.2014.12.007 · DOI
- Holcik, 2015, Could the eIF2alpha-independent translation be the Achilles heel of cancer?, Front Oncol, 5, 264, 10.3389/fonc.2015.00264 · DOI · Paper page
- Somers, 2015, A common polymorphism in the 5’ UTR of ERCC5 creates an upstream ORF that confers resistance to platinum-based chemotherapy, Genes Dev, 29, 1891, 10.1101/gad.261867.115 · DOI
- Richter, 2015, Pausing on polyribosomes: make way for elongation in translational control, Cell, 163, 292, 10.1016/j.cell.2015.09.041 · DOI · Paper page
- Reid, 2015, Diversity and selectivity in mRNA translation on the endoplasmic reticulum, Nat Rev Mol Cell Biol, 16, 221, 10.1038/nrm3958 · DOI · Paper page
- Jagannathan, 2014, Multifunctional roles for the protein translocation machinery in RNA anchoring to the endoplasmic reticulum, J Biol Chem, 289, 25907, 10.1074/jbc.M114.580688 · DOI
- Reid, 2012, Primary role for endoplasmic reticulum-bound ribosomes in cellular translation identified by ribosome profiling, J Biol Chem, 287, 5518, 10.1074/jbc.M111.312280 · DOI · Paper page
- Chaudhury, 2010, TGF-beta-mediated phosphorylation of hnRNP E1 induces EMT via transcript-selective translational induction of Dab2 and ILEI, Nat Cell Biol, 12, 286, 10.1038/ncb2029 · DOI · Paper page
- Hussey, 2011, Identification of an mRNP complex regulating tumorigenesis at the translational elongation step, Mol Cell, 41, 419, 10.1016/j.molcel.2011.02.003 · DOI · Paper page
- Ryazanov, 1988, Phosphorylation of elongation factor 2 by EF-2 kinase affects rate of translation, Nature, 334, 170, 10.1038/334170a0 · DOI · Paper page
- Faller, 2015, mTORC1-mediated translational elongation limits intestinal tumour initiation and growth, Nature, 517, 497, 10.1038/nature13896 · DOI · Paper page
- Liu, 2014, Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K, EMBO Mol Med, 6, 1542, 10.15252/emmm.201404402 · DOI · Paper page
- Xue, 2012, Specialized ribosomes: a new frontier in gene regulation and organismal biology, Nat Rev Mol Cell Biol, 13, 355, 10.1038/nrm3359 · DOI · Paper page
- Novoa, 2012, Speeding with control: codon usage, tRNAs, and ribosomes, Trends Genet, 28, 574, 10.1016/j.tig.2012.07.006 · DOI · Paper page
- Pavon-Eternod, 2013, Overexpression of initiator methionine tRNA leads to global reprogramming of tRNA expression and increased proliferation in human epithelial cells, RNA, 19, 461, 10.1261/rna.037507.112 · DOI · Paper page
- Felton-Edkins, 2003, Direct regulation of RNA polymerase III transcription by RB, p53 and c-Myc, Cell Cycle, 2, 181, 10.4161/cc.2.3.375 · DOI · Paper page
- Felton-Edkins, 2003, The mitogen-activated protein (MAP) kinase ERK induces tRNA synthesis by phosphorylating TFIIIB, EMBO J, 22, 2422, 10.1093/emboj/cdg240 · DOI
- Gingold, 2014, A dual program for translation regulation in cellular proliferation and differentiation, Cell, 158, 1281, 10.1016/j.cell.2014.08.011 · DOI · Paper page
- Pavon-Eternod, 2009, tRNA over-expression in breast cancer and functional consequences, Nucleic Acids Res, 37, 7268, 10.1093/nar/gkp787 · DOI · Paper page
- Grewal, 2015, Why should cancer biologists care about tRNAs? tRNA synthesis, mRNA translation and the control of growth, Biochim Biophys Acta, 1849, 898, 10.1016/j.bbagrm.2014.12.005 · DOI
- Gu, 2014, tRNA modifications regulate translation during cellular stress, FEBS Lett, 588, 4287, 10.1016/j.febslet.2014.09.038 · DOI · Paper page
- Park, 2008, Aminoacyl tRNA synthetases and their connections to disease, Proc Natl Acad Sci U S A, 105, 11043, 10.1073/pnas.0802862105 · DOI · Paper page
- Jia, 2008, WHEP domains direct noncanonical function of glutamyl-prolyl tRNA synthetase in translational control of gene expression, Mol Cell, 29, 679, 10.1016/j.molcel.2008.01.010 · DOI · Paper page
- McCune, 1979, Neoplastic transformation-linked alterations in arginyl-tRNA synthetase activity, Biochim Biophys Acta, 561, 410, 10.1016/0005-2787(79)90149-7 · doi:10.1016/0005-2787(79)90149-7
- Thomas, 1982, Comparison of complexes containing lysyl-tRNA synthetase from normal and virus-transformed cells, Can J Biochem, 60, 804, 10.1139/o82-100 · doi:10.1139/o82-100
- Kim, 2011, Aminoacyl-tRNA synthetases and tumorigenesis: more than housekeeping, Nat Rev Cancer, 11, 708, 10.1038/nrc3124 · DOI · Paper page
Cited by
The somatic molecular evolution of cancer: Mutation, selection, and epistasis
Dasari, K., Somarelli, J. A., Kumar, S., & Townsend, J. P. (2021) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2021.08.003 · Cited by 22
(2025) · doi:10.1038/s41467-024-54176-3 · Cited by 4
Zhang, Y., Leung, A. K., Kang, J. J., Sun, Y., Wu, G., Li, L., Sun, J., Cheng, L., Qiu, T., Zhang, J., et al. (2023) · doi:10.1101/2023.03.06.531441
Metadata
- Authors
- Vaklavas, C., Blume, S. W., & Grizzle, W. E.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2017-07-26
- Volume
- 7
- Pages
- 158-158
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W2738737902
- Cited by
- 73
- References
- 23
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- Susan G. Komen for the Cure (CCR15331062)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.